Become an Exhibitor
Study Shows Initial Aortic Valve Replacement in Asymptomatic Patients with Severe Aortic Stenosis May Be a Viable Treatment Option
SAN FRANCISCO – October 15, 2015 – A large observational registry found that initial aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS) was associated with a lower risk of mortality and heart failure hospitalization compared with a conservative treatment strategy.
Favorable Results at One Year with Newest Generation of Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients with Aortic Stenosis
SAN FRANCISCO – October 15, 2015 – One-year patient outcomes from the PARTNER II trial showed that the low rate of 30-day complications with balloon-expandable transcatheter aortic valve replacement (TAVR) in high-risk and inoperable patients with aortic stenosis persisted with follow up to one year.
Long-Term Study Results Show that PFO Closure May Be Effective in Preventing Recurrent Cryptogenic Stroke, Particularly in Younger Patients
SAN FRANCISCO – October 15, 2015 – Long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an AMPLATZER PFO Occluder was superior to medical management in the prevention of recurrent cryptogenic stroke in patients who previously had a cryptogenic stroke.
Similar Results with Bivalirudin Compared with Heparin Anticoagulation in TAVR Patients
SAN FRANCISCO – October 15, 2015 – Results from the BRAVO 3 trial found that bivalirudin did not reduce significantly rates of major bleeding at 48 hours or adverse events at 30 days compared to heparin in high risk patients undergoing transcatheter aortic valve replacement (TAVR).